According to TipRanks.com, Stringer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.1% and a 29.4% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Lexicon Pharmaceuticals, and Phathom Pharmaceuticals.
Moderna has an analyst consensus of Hold, with a price target consensus of $328.00, representing a -23.3% downside. In a report issued on September 7, Morgan Stanley also maintained a Hold rating on the stock with a $337.00 price target.
The company has a one-year high of $497.49 and a one-year low of $63.64. Currently, Moderna has an average volume of 17.51M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Read More on MRNA:
- Needham Releases a Buy Rating on Overstock (OSTK)
- H.C. Wainwright Remains a Buy on Innate Pharma (IPHA)
- Entasis Therapeutics Holdings (ETTX) Gets a Buy Rating from H.C. Wainwright
- H.C. Wainwright Believes Crinetics Pharmaceuticals (CRNX) Still Has Room to Grow
- Needham Sticks to Their Buy Rating for Aerie Pharma (AERI)